Healthcare Triangle, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
HCTI$4.21-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | |||
|---|---|---|---|
| Note | 2025 | 2024 | |
| Cash flows from operating activities | |||
| Net (loss) | $(4,973) | $(4,621) | |
| Adjustment to reconcile net (loss) to net cash provided by / (used in) operating activities | |||
| Depreciation & amortization | 75 | 1,034 | |
| Reversal for current expected credit loss | (20) | - | |
| Change in fair value of warrants | - | 379 | |
| Net unrealized exchange loss | 8 | - | |
| Common stock issued for services | 88 | 22 | |
| Amortization of debt discount | 223 | 217 | |
| Other income | (683) | - | |
| Stock compensation expenses | 6 | 451 | 106 |
| Interest expenses | 467 | - | |
| Interest expenses settled by equity | 316 | - | |
| Changes in working capital: | |||
| (Increase) / decrease in: | |||
| Accounts receivable | (1,247) | 1,626 | |
| Other current assets | (40) | 678 | |
| Due from affiliates | 3.6 | (3,005) | 304 |
| Accounts payable | (1,377) | 345 | |
| Other current liabilities | 28 | (360) | |
| Net cash used in operating activities | (9,689) | (270) | |
| Cash flows from investing activities | |||
| Purchase of furniture and equipment | (6) | - | |
| Acquisition of intangible assets | 3.3 | (1,283) | - |
| Net cash used in investing activities | (1,289) | - | |
| Cash flows from financing activities | |||
| Decrease in short term borrowing | 3.9 | (1,251) | (1,892) |
| Interest paid | (467) | - | |
| Net proceeds from equity issuance | 14,305 | 956 | |
| Net cash provided by / (used in) financing activities | 12,587 | (936) | |
| Net changes in cash and cash equivalents | 1,609 | (1,206) | |
| Cash and cash equivalents | |||
| Cash and cash equivalents at the beginning of the period | $20 | $1,234 | |
| Cash and cash equivalents at the end of the period | $1,629 | $28 | |
| Non-cash investing and financing activities | |||
| Supplementary disclosure of cash flows information | |||
| Interest | - | 360 | |
| Income taxes | - | 8 | |
| Equity to be issued | 3,000 | - | |
| Conversion of convertible note | - | 1,181 | |
| Acquisition of assets | 1,200 | - | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.